STOCK TITAN

Aura Biosciences grants Person 107,611 RSUs, options

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aura Biosciences, Inc. (AURA) reported that Chief People Officer Julie Person received 107,611 shares of Common Stock in the form of restricted stock units (RSUs) as an inducement award, and a stock option for 212,389 shares with an exercise price of $7.43 per share.

The RSUs vest in four substantially equal annual installments starting September 15, 2027, conditioned on continued service. The stock option vests 25% on August 12, 2027, with the remaining 75% vesting pro-rata in 36 monthly installments, also subject to continued service, and expires on September 1, 2036.

Positive

  • None.

Negative

  • None.
Insider Person Julie
Role Chief People Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F2 212,389 $0.00 $0.00
Grant/Award Common Stock F1 107,611 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 212,389 contracts (Direct); Common Stock — 107,611 shares (Direct)
Footnotes (2)
  1. F1. These securities represent an inducement award granted pursuant to a restricted stock unit ("RSU") award agreement with the Issuer. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments, subject to the Reporting Person's continued service as of the relevant vesting date, with the first tranche scheduled to vest on September 15, 2027.
  2. F2. The option shall vest as follows: 25% of the options vest on August 12, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
RSU shares granted 107,611 shares Restricted stock unit inducement award to Chief People Officer on September 1, 2026
Option shares granted 212,389 shares Stock option grant to Chief People Officer on September 1, 2026
Option exercise price $7.43 per share Conversion or exercise price for 212,389-share stock option
Option expiration date September 1, 2036 Expiration date of stock option covering 212,389 shares
Common Stock held after RSU grant 107,611 shares Direct Common Stock position following RSU inducement award
Underlying Common Stock for option 212,389 shares Underlying Common Stock associated with reported stock option grant
restricted stock unit ("RSU") financial
"These securities represent an inducement award granted pursuant to a restricted stock unit ("RSU") award agreement"
inducement award financial
"These securities represent an inducement award granted pursuant to a restricted stock unit"
An inducement award is a special cash or equity payment given to a new hire—often an executive or key employee—outside the company’s regular pay plans to persuade them to join. Think of it like a signing bonus that can align the new person’s goals with shareholders but also represents a cost and can reduce existing owners’ percentage of the company, so investors watch these awards for their impact on ownership and future performance.
vest financial
"These RSUs vest in four substantially equal annual installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
pro-rata financial
"with the remainder vesting thereafter pro-rata in 36 monthly installments"
Pro-rata means an amount is allocated to each party in proportion to their existing share or stake — each person receives the same percentage of the total as they already hold. For investors this matters because pro-rata rules determine how much additional stock, dividends, or voting power someone gets during new issuances or distributions, helping protect an investor’s relative ownership; think of it as slicing a cake so everyone keeps the same-sized slice relative to others.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)"

FAQ

What equity awards did AURA grant to Chief People Officer Julie Person?

Julie Person received 107,611 RSUs of Aura Biosciences Common Stock and a stock option for 212,389 shares with an exercise price of $7.43 per share, all reported as direct ownership grants on September 1, 2026.

How do the new RSUs for AURA’s Chief People Officer vest?

The 107,611 RSUs vest in four substantially equal annual installments, subject to continued service, with the first tranche scheduled to vest on September 15, 2027.

What are the vesting terms of the new stock option reported by AURA?

The stock option for 212,389 shares vests 25% on August 12, 2027, with the remaining 75% vesting pro-rata in 36 monthly installments, contingent on Julie Person’s continued service on each vesting date.

What is the exercise price and expiration date of the new AURA stock option?

The reported stock option has an exercise price of $7.43 per share and an expiration date of September 1, 2036, covering 212,389 shares of Aura Biosciences Common Stock.

How many AURA shares does Julie Person hold after these reported equity grants?

Following these transactions, Julie Person is reported to directly hold 107,611 shares of Common Stock from RSUs and 212,389 option shares underlying the granted stock option, as shown in the post-transaction holdings fields.

Are the AURA equity awards to Julie Person part of an inducement arrangement?

Yes. The filing states the 107,611 RSUs are an inducement award granted pursuant to an RSU award agreement, with each RSU representing the right to receive one share of Aura Biosciences Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Person Julie

(Last)(First)(Middle)
C/O AURA BIOSCIENCES, INC.
80 GUEST STREET

(Street)
BOSTON MASSACHUSETTS 02135

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief People Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/01/2026A107,611(1)A$0107,611D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$7.4309/01/2026A212,389 (2)09/01/2036Common Stock212,389$0212,389D
Explanation of Responses:
1. These securities represent an inducement award granted pursuant to a restricted stock unit ("RSU") award agreement with the Issuer. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments, subject to the Reporting Person's continued service as of the relevant vesting date, with the first tranche scheduled to vest on September 15, 2027.
2. The option shall vest as follows: 25% of the options vest on August 12, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
/s/ Amy Elazzouzi, as Attorney-in-Fact09/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)